- Home
- VNRX
VNRX
VolitionRX Limited
as 03-27-2025 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 58.6M | IPO Year: | N/A |
| Target Price: | $4.17 | AVG Volume (30 days): | 111.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $1.02 | Next Earning Date: | 05-12-2025 |
| Revenue: | $1,285,827 | Revenue Growth: | 97.50% |
| Revenue Growth (this year): | 71446.31% | Revenue Growth (next year): | -97.97% |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
PR Newswire
3 days ago
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
MT Newswires
7 days ago
VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development
PR Newswire
7 days ago
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
PR Newswire
8 days ago
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
PR Newswire
11 days ago
Volition Proudly Sponsors the 44th ISICEM Congress
MT Newswires
15 days ago
VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems
PR Newswire
15 days ago
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Compare VNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.